Osama Gheith,Ibraheim, MonaSaied, TarekMuzeirei, IbraheemAl-Waheeb, SalahNair, PrasadHalim, MedhatNampoory, NarayananAl-Otaibi, Torki2026-04-102012-08Experimental and Clinical Transplantation, Cilt, 10, Sayı, 4, 2012 ss. 406-4091304-0855https://hdl.handle.net/11727/14900To reduce the long-term toxicities of immuno­suppressant drugs, corticosteroid-sparing and calcineurin-inhibitor–sparing immunosuppression protocols have become increasingly popular in managing kidney transplant recipients. The most vexing clinical condition caused by antibodies in organ transplants is antibody-mediated rejection. Limitations of the current antibody-mediated rejection therapies include (1) antibody-mediated rejection reversal tends to be gradual rather than prompt, (2) expense, (3) rejection reversal rates below 80%, (4) common appearance of chronic rejection after antibody-mediated rejection treatment, and (5) long-term persistence of donor specific antibodies after therapy. Because these limitations may be due to a lack of effects on mature plasma cells, the effects of bortezomib on mature plasma cells may represent a quantum advance in antihumoral therapy. Our experiences represent the first clinical use of bortezomib as an antihumoral agent in renal allograft recipients in Kuwait. We present 2 cases with resistant-acute antibody-mediated rejection to the standard therapies that were managed successfully with bortezomib.enAntibody-mediated rejectionBortezomibRenal transplantCase Report1042146-8427